Dimethoxycurcumin Acidifies Endolysosomes and Inhibits SARS-CoV-2 Entry

Dimethoxycurcumin Acidifies Endolysosomes and Inhibits SARS-CoV-2 Entry

The pandemic of coronavirus disease 2019 (COVID-19) caused by infection by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) continues to take a huge toll on global health. Although improving, currently there are only limited therapies against SARS-CoV-2. Curcumin, a natural polyphenol, e...

Full description

Bibliographic Details
Main Authors:	Nabab Khan, Zahra Afghah, Aparajita Baral, Jonathan D. Geiger, Xuesong Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Virology
Subjects:	dimethoxycurcumin ACE2 (angiotensin converting enzyme-2) lysosome acidification SARS-CoV-2
Online Access:	https://www.frontiersin.org/articles/10.3389/fviro.2022.923018/full

Similar Items

Effect of dimethoxycurcumin beyond degradation of androgen receptor
by: Wei-Ming Wang, et al.
Published: (2011-12-01)

The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19
by: Francesca Silvagno, et al.
Published: (2020-07-01)

The Endolysosomal System: The Acid Test for SARS-CoV-2
by: Daniella Cesar-Silva, et al.
Published: (2022-04-01)

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
by: Tümay Capraz, et al.
Published: (2021-12-01)

Evaluation of the Association between Multilobar Involvement and ACE Inhibitor Use in SARS-CoV-2 Patients
by: Dilay Satilmis, et al.
Published: (2023-01-01)

Circulating Soluble ACE2 Plays an Independent Role to Protect against Vascular Damage in Diabetic Mice
by: Chris Tikellis, et al.
Published: (2022-05-01)

Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice
by: Ping Su, et al.
Published: (2022-08-01)

ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues
by: Sally Badawi, et al.
Published: (2021-01-01)

SARS-CoV-2 Infection and Oral Health: Therapeutic Opportunities and Challenges
by: Christopher J. Coke, et al.
Published: (2021-01-01)

Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19
by: Artemio García-Escobar, et al.
Published: (2022-01-01)

Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
by: Cosimo Cianfarini, et al.
Published: (2024-01-01)

COVID-19: Gender and Outcomes
by: Alfonso Ilardi
Published: (2022-04-01)

Purification and Characterization of Porcine Angiotensin Converting Enzyme 2
by: Weiwei LIU, et al.
Published: (2022-09-01)

The Future of the COVID-19 Pandemic: How Good (or Bad) Can the SARS-CoV2 Spike Protein Get?
by: Matthew A. Nugent
Published: (2022-03-01)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
by: Dean Gilham, et al.
Published: (2021-04-01)

Neuropsychiatric Disorders and COVID-19: What We Know So Far
by: Fernanda Majolo, et al.
Published: (2021-09-01)

Characterization of ACE2 naturally occurring missense variants: impact on subcellular localization and trafficking
by: Sally Badawi, et al.
Published: (2022-09-01)

Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer’s Disease
by: Qiyue Ding, et al.
Published: (2021-02-01)

Generation and Characterization of a SARS-CoV-2-Susceptible Mouse Model Using Adeno-Associated Virus (AAV6.2FF)-Mediated Respiratory Delivery of the Human ACE2 Gene
by: Nikesh Tailor, et al.
Published: (2022-12-01)

Angiotensin-Converting Enzyme 2 (ACE2) as a Potential Diagnostic and Prognostic Biomarker for Chronic Inflammatory Lung Diseases
by: Dejan Marčetić, et al.
Published: (2021-07-01)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
by: Marc A. Simon, et al.
Published: (2022-01-01)

The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences
by: Minela Aida Maranduca, et al.
Published: (2022-09-01)

Spike protein of SARS-CoV-2 suppresses gonadotrophin secretion from bovine anterior pituitaries
by: Dimas Arya ABDILLAH, et al.
Published: (2022-01-01)

Angiotensin II and COVID-19. Secrets of interactions
by: A. O. Konradi, et al.
Published: (2020-05-01)

Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases
by: Hamid Tanzadehpanah, et al.
Published: (2023-10-01)

Angiotensin-converting enzyme 2. Approaches to pathogenetic therapy of COVID-19
by: Polina O. Shatunova, et al.
Published: (2020-09-01)

Predictive Models of within- and between-Species SARS-CoV-2 Transmissibility
by: Ricardo Soares, et al.
Published: (2022-07-01)

Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2
by: Reza Zolfaghari Emameh, et al.
Published: (2020-06-01)

Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein
by: Loai M. Saadah, et al.
Published: (2020-11-01)

Chemotherapy induces ACE2 expression in breast cancer via the ROS-AKT-HIF-1α signaling pathway: a potential prognostic marker for breast cancer patients receiving chemotherapy
by: Xiaoyan Zuo, et al.
Published: (2022-11-01)

Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells
by: Ilaria Caputo, et al.
Published: (2022-05-01)

The pH Effects on SARS-CoV and SARS-CoV-2 Spike Proteins in the Process of Binding to hACE2
by: Yixin Xie, et al.
Published: (2022-02-01)

Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors
by: Ling Ma, et al.
Published: (2023-02-01)

The Role of ACE, ACE2, and AGTR2 Polymorphisms in COVID-19 Severity and the Presence of COVID-19-Related Retinopathy
by: Kristina Jevnikar, et al.
Published: (2022-06-01)

COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice
by: Cathleen Lutz, et al.
Published: (2020-06-01)

Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
by: Enrique Ambrocio-Ortiz, et al.
Published: (2021-08-01)

Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules
by: Kenana Al Adem, et al.
Published: (2020-12-01)

Potential Antiviral Strategy Exploiting Dependence of SARS-CoV-2 Replication on Lysosome-Based Pathway
by: Yungang Lan, et al.
Published: (2022-05-01)

New Frontiers in The Intrarenal Renin-Angiotensin System: A Critical Review of Classical and New Paradigms
by: Jia L Zhuo, et al.
Published: (2013-11-01)

Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19
by: Tomas Rajtik, et al.
Published: (2021-11-01)